News & Events
-
Sachs Associates 21st Annual Biotech in Europe Forum (BEF)
When:
Anima Biotech has been invited to participate during the virtual 21st Annual Biotech in Europe Forum (BEF) hosted by Sachs Associates. Yochi Slonim, Co-founder and CEO, will serve as an expert on the “Platform Technologies & Novel Therapeutics” panel. The event will include BioCapital & Investment Day and Bio-Pharma Partnering & Therapeutics Day. The two days will feature more than 15 hours of high-level speeches, panel discussions and spotlight showcases by leading industry corporates. In addition, there is a global company showcase of 50+ presentations by established public, private, emerging and seed companies, offering innovative solutions and seeking investment and partnering opportunities.
-
UBS Biotechnology Private Company Symposium
When:
Anima Biotech has been invited to give a presentation during the UBS Biotechnology Private Company Symposium. Yochi Slonim, Co-founder and CEO, will provide a corporate update to those registered for the conference. At more than 300 conferences a year across Europe, Asia Pacific and the Americas, UBS connects corporate leaders and the global investor community, influential policy makers and industry experts. UBS’ award-winning analysts and economists debate the big ideas, trends and challenges shaping the environment, bringing attendees local knowledge with global perspective.
-
3rd Annual RAS-Targeted Drug Development Summit
When:
Anima Biotech has been invited to participate on an expert panel during the 3rd Annual RAS-Targeted Drug Development meeting. Iris Alroy, Ph.D., Vice President of Research and Development of Anima Biotech, will participate as an expert on a panel titled, “Exploring Chemistry Between Mutations: How to Exploit Mutations for Selective Targeting.” This year’s meeting will mark the largest summit in the RAS series to date. After decades of R&D efforts into targeted KRAS therapies, this year’s summit will serve as an all-inclusive program addressing emerging strategies to target all RAS mutations, robust and effective combination strategies and shining a spotlight onto optimized clinical translation and clinical trials in progress.
-
Undruggable Leaders Forum
When:
Anima Biotech has been invited to participate in the 2021 Undruggable Leaders Forum. Yochi Slonim, CEO, will serve as an expert during a fireside chat alongside Beth Shafer, Head of Neuroscience, Drug Discovery Sciences and Externalization Business Development at Takeda. This session will explore Anima-Takeda collaboration for the discovery and development of mRNA translation modulators for Neurological diseases. The Undruggable Leaders Forum was established with the mission of uniting key experts to discuss the latest scientific developments and clinical breakthroughs in diseases currently deemed “undruggable.”
-
5th IPF Summit 2021
When:
Anima Biotech has been invited to give a presentation at the 5th Annual Idiopathic Pulmonary Fibrosis (IPF) Summit. Iris Alroy, Vice President of Research and Development of Anima Biotech, will give a presentation titled, “Multiple mechanisms for Collagen mRNA translation regulation in IPF: from mRNA processing to mRNA translation.” The 5th IPF Summit will be an opportunity to learn from industry experts and gain the knowledge needed to tackle tough translational and clinical hurdles to ultimately develop more reliable, effective and disease modifying IPF drugs. Speakers will present innovative research and provide updates on state-of-the-art science to make meaningful impact on the lives of the 3 million patients suffering with IPF worldwide.
-
Anima Biotech achieves first milestone in Takeda collaboration
The milestone relates to the Huntington’s Disease program which is part of a multi-target research collaboration between the companies. This achievement entitles
Anima to an undisclosed milestone payment.“Since announcing our partnership with Anima back in March, our research collaboration has kicked off to a success with the achievement of this first milestone,” said Ceri Davies Head, Neuroscience Drug Discovery Unit at Takeda.
“We are delighted to announce this successful milestone in our strategic collaboration with Takeda which demonstrates the advantage of our approach with small molecule mRNA drugs. We are highly motivated to keep advancing the Huntington’s Disease program and the overall collaboration” said Yochi Slonim, Anima’s co-founder & CEO.
-
UBS Innovation Series: The Next Wave in Neurodegeneration
When:
Anima Biotech has been invited to participate in a presentation at the UBS Innovation Series: The Next Wave in Neurodegeneration. The presentation by Yochi Slonim, CEO, will feature Anima Biotech’s proprietary technology platform and its use in developing mRNA translation modulators for neurodegenerative disorders, such as Alzheimer’s disease. The virtual conference will shed light on the latest advancements in neurodegeneration.
-
Cambridge Healthtech Institute’s 2nd Annual RNA-Targeting Small Molecule Drugs
When:
Anima Biotech has been invited to participate in both a presentation and a live panel discussion at the Cambridge Healthtech Institute’s 2nd Annual RNA-Targeting Small Molecule Drugs Conference. Iris Alroy, Ph.D., Vice President of Research and Development of Anima Biotech, will give a presentation titled, “Targeting mRNA Translation in a Tissue Selective and Disease-Specific Manner with Small Molecules.” Additionally, Dr. Alroy will serve as an expert on a panel during the virtual meeting. The conference was established to highlight some of the innovative approaches being pursued to find new small molecule drugs for targeting RNA for therapeutics intervention.
-
Sachs 4th Annual Neuroscience Innovation Forum
When:
Anima Biotech has been invited to participate in a live panel discussion at the Sachs 4th Annual Neuroscience Innovation Forum. Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, will serve as an expert on a panel titled, “Pharma Partnering and M&A: An Update on DealMaking Panel.” The virtual conference will feature more than 14 hours of high-level speeches, panel discussions and spotlight showcases by leading industry experts. The target audience for this event are buy and sell-side analysts from investment banks and funds, as well as partnering executives from pharma, biotech and medtech companies.
-
1st Interstitial Lung Disease Drug Development Summit
When:
Anima Biotech has been invited to give a presentation at the 1st Interstitial Lung Disease Drug Development Summit. Iris Alroy, Vice President of Research and Development of Anima Biotech, will give a presentation titled, “Targeting Collagen I mRNA Translation in a Tissue Selective Manner with Small Molecules.” The 1st ILD Summit is a new and groundbreaking conference dedicated to helping industry drive forward the development of effective therapies for chronic fibrosing ILDs and achieve success in anti-fibrotic drug development beyond IPF. During the virtual conference, leading experts will share critical insights to help attendees define, understand and develop clinically effective antifibrotic therapies against the progressive fibrosing ILD phenotype Scleroderma, Sjogren’s Syndrome, Sarcoidosis, Hypersensitivity Pneumonitis and more.